Skip to main content

Clinical Trials › NCT04047628

RecruitingPhase 3

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
156
Target enrollment
15
U.S. states
Dec 2019
Start date
Oct 2029
Expected completion

Interventions / Treatments

Autologous Hematopoietic Stem Cell TransplantationBest Available Therapy (BAT)

Conditions studied

Relapsing Multiple SclerosisRelapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis

Where this trial is running (22 sites)

Washington3 sites
Seattle · Seattle · Seattle
Minnesota2 sites
Minneapolis · Rochester
New York2 sites
New York · Rochester
Ohio2 sites
Cincinnati · Cleveland
Texas2 sites
Dallas · Houston
Virginia2 sites
Charlottesville · Richmond
Palo Alto
Colorado1 site
Aurora
Illinois1 site
Evanston
Worcester
Missouri1 site
St Louis
Durham
Oregon1 site
Portland
Philadelphia
Wisconsin1 site
Milwaukee

MS centers in Washington

Compare treatment centers near a trial site by center type, providers and trials.

View Washington centers

More Phase 3 trials

Browse all Phase 3 MS trials
The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play